What is the 13F Pro Quality Score for EYPT?

13F Pro ranks EyePoint, Inc. (EYPT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EYPT's current score at https://13fpro.ai/research/EYPT (free sign-up required for the full ranking).

Where does 13F Pro source EYPT data?

All EyePoint, Inc. fundamentals and ownership data come directly from SEC EDGAR. EyePoint, Inc. files with the SEC under CIK 1314102. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EYPT in?

EyePoint, Inc. (EYPT) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

How often is EYPT research updated on 13F Pro?

EYPT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

EyePoint, Inc.(EYPT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1314102 EYPT stock profile & AI dashboard →

13F Pro Quality Score

10.3/100

Rank #2,810 of 2,879 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

8.4/100

Profitability

2.8/100

Balance Sheet

1.8/100

Earnings Quality

30.0/100

Free Cash Flow

2.5/100

Institutional Flow

91.8/100

Revenue Scale

7.8/100

Dilution Risk

3.4/100

EYPT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for EyePoint, Inc. (EYPT), a Technology sector company. 13F Pro's AI-powered ranking engine scores EYPT at 10.3/100 on a 32-signal composite quality model, placing it at rank #2,810 of 2,879 stocks — the bottom half of the AI-ranked universe. EYPT scores in the top quartile across institutional flow (91.8). Areas of concern include balance sheet strength (1.8) and free cash flow (2.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), EyePoint, Inc. reports quarterly revenue of $696.0K, net income of $-84.8M, free cash flow of $-81.5M. Top institutional holders of EYPT by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, Cormorant Asset Management,, BlackRock,, based on the most recent SEC filings. EYPT trades on the Nasdaq exchange and files with the SEC under CIK 1314102. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EYPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EyePoint, Inc. directly from SEC EDGAR. EyePoint, Inc.'s 13F Pro composite quality score has ranged between 8 and 39 since 2026, currently 10.3 — a stable long-term trajectory across 36 quarterly and live scoring snapshots.

✦

Fun facts about EyePoint, Inc.

Quirks, history, and lore behind EYPT — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company focused on specialty drug delivery · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenues in the low tens of millions of dollars — classic commercial-stage micro-cap territory, where every product approval is a make-or-break moment.
3
The History
The company traces its roots to work on sustained-release ocular implants — tiny devices that park a drug directly inside the eye for months at a time.
4
The Secret
Its proprietary Durasert platform is the secret sauce — a biodegradable or non-biodegradable implant technology licensed to bigger pharma partners as well as fielded in its own products.
5
The Lore
One of its flagship products targets chronic non-infectious uveitis affecting the posterior segment of the eye — a mouthful of a disease that affects a small but desperate patient population.
6
The Giveaway
The ticker practically spells out the mission: this eye-focused drug-delivery company, with EYPT on Nasdaq, wants to be the go-to name in long-lasting ocular therapeutics.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$696.0K

Net Income

Q3 2026

$-84.8M

Free Cash Flow

Q3 2026

$-81.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-60.7% YoY

$3.0MFY 2018

FY15 $26.6MFY16 $1.6MFY17 $7.5MFY18 $3.0M

Net Income

-187.6% YoY

$-53.2MFY 2018

FY15 $6.3MFY16 $-21.5MFY17 $-18.5MFY18 $-53.2M

Operating Income

-41.4% YoY

$-26.3MFY 2018

FY15 $6.4MFY16 $-21.8MFY17 $-18.6MFY18 $-26.3M

EPS (Diluted)

—FY 2018

FY15 $0.21FY16 $-0.68FY17 $-0.52FY18 —

Total Assets

+283.7% YoY

$71.7MFY 2018

FY15 $32.4MFY16 $31.6MFY17 $18.7MFY18 $71.7M

Total Debt

$17.3MFY 2018

FY15 —FY16 —FY17 $0.00FY18 $17.3M

Op. Cash Flow

-6.9% YoY

$-21.9MFY 2018

FY15 —FY16 $-16.3MFY17 $-20.5MFY18 $-21.9M

Metric	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Revenue	$3.0M -60.7%	$7.5M +365.4%	$1.6M -93.9%	$26.6M +664.9%	$3.5M +62.1%	$2.1M
Net Income	$-53.2M -187.6%	$-18.5M +14.2%	$-21.5M -439.5%	$6.3M +147.5%	$-13.4M -12.2%	$-11.9M
Operating Income	$-26.3M -41.4%	$-18.6M +14.7%	$-21.8M -439.1%	$6.4M +147.6%	$-13.5M -12.1%	$-12.0M
EPS (Diluted)	—	$-0.52 +23.5%	$-0.68 -423.8%	$0.21 +142.9%	$-0.49 +5.8%	$-0.52
Total Assets	$71.7M +283.7%	$18.7M -40.9%	$31.6M -2.3%	$32.4M +42.8%	$22.7M +39.5%	$16.2M
Total Debt	$17.3M	$0.00	—	—	—	—
Operating Cash Flow	$-21.9M -6.9%	$-20.5M -25.6%	$-16.3M	—	—	$-8.7M

Get alerted when EYPT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for EyePoint, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EYPT

SUVRETTA CAPITAL MANAGEMENT, LLC
$106.9M8,296,375 sh
Cormorant Asset Management, LP
$106.5M8,265,000 sh
BlackRock, Inc.
$92.5M7,177,337 sh
FEDERATED HERMES, INC.
$73.1M5,669,589 sh
FRANKLIN RESOURCES INC
$65.1M5,048,598 sh
JANUS HENDERSON GROUP PLC
$46.4M3,601,168 sh
VANGUARD CAPITAL MANAGEMENT LLC
$45.9M3,559,569 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$42.5M3,300,000 sh
Paradigm Biocapital Advisors LP
$40.5M3,142,437 sh
Commodore Capital LP
$36.4M2,825,000 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$106.9M	8,296,375
Cormorant Asset Management, LP	$106.5M	8,265,000
BlackRock, Inc.	$92.5M	7,177,337
FEDERATED HERMES, INC.	$73.1M	5,669,589
FRANKLIN RESOURCES INC	$65.1M	5,048,598
JANUS HENDERSON GROUP PLC	$46.4M	3,601,168
VANGUARD CAPITAL MANAGEMENT LLC	$45.9M	3,559,569
ADAGE CAPITAL PARTNERS GP, L.L.C.	$42.5M	3,300,000
Paradigm Biocapital Advisors LP	$40.5M	3,142,437
Commodore Capital LP	$36.4M	2,825,000

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put EYPT on your watchlist

Track score changes the day EyePoint, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EYPT a good stock to buy?

13F Pro's AI-powered analysis of EyePoint, Inc. (EYPT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EYPT are available on the EYPT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own EYPT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EYPT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of EyePoint, Inc.'s investment landscape.